Effect of pomaglumetad methionil on the QT interval in subjects with schizophrenia

International Journal of Clinical Pharmacology and Therapeutics

Volumn 53, Issue 6, 2015, Pages 462-470

  Zhang, Wei ^a   Mitchell, Malcolm I ^a   Knadler, Mary Pat ^a   Long, Amanda ^a   Witcher, Jennifer ^a   Walling, David ^b   Annes, William ^a   Ayan Oshodi, Mosun ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Collaborative Neuroscience Network Inc ^*  (United States)

Author keywords

Pomaglumetad; QT ; Thorough QT study

Indexed keywords

MOXIFLOXACIN; PLACEBO; POMAGLUMETAD METHIONIL; AMINO ACID; AMINO ACID RECEPTOR STIMULATING AGENT; PRODRUG;

ABDOMINAL PAIN; ADULT; ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DSM-IV-TR; DYSKINESIA; ELECTROCARDIOGRAPHY; FEMALE; GASTROINTESTINAL DISEASE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NEUROLOGIC DISEASE; PHASE 1 CLINICAL TRIAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RETCHING; SCHIZOPHRENIA; SINGLE DRUG DOSE; TREATMENT OUTCOME; VOMITING; WEAKNESS; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; DRUG MONITORING; HEART RATE; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PSYCHOLOGY; REGRESSION ANALYSIS; RISK ASSESSMENT; UNITED STATES; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AMINO ACIDS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUG MONITORING; ELECTROCARDIOGRAPHY; EXCITATORY AMINO ACID AGONISTS; FEMALE; HEART RATE; HUMANS; LEAST-SQUARES ANALYSIS; MALE; MIDDLE AGED; PRODRUGS; RISK ASSESSMENT; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 84936756380     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202289     Document Type: Article

References (22)

1. Kinon BJ, Gómez JC. Clinical development of pomaglumetad methionil: a non-dopaminergic treatment for schizophrenia. Neuropharmacology. 2013; 66: 82-86. CrossRef PubMed
2. Schoepp DD, Marek G. J. Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia? Curr Drug Targets. CNS Neurol Disord Drug Targets. 2002; 1: 215-225. Cross-Ref
3. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med. 2007; 13: 1102-1107. CrossRef PubMed
4. Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012; 37: 4-15. CrossRef PubMed
5. Food and Drug Administration. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. E14 clinical evaluation of QT/QTC interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs. 2005; http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm073153.pdf.
6. Haddad PM, Anderson IM. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death. Drugs. 2002; 62: 1649-1671. CrossRef PubMed
7. Fitzgerald PT, Ackerman MJ. Drug-induced torsades de pointes: the evolving role of pharmacogenetics. Heart Rhythm. 2005; 2 (Suppl): S30-S37. CrossRef PubMed
8. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001; 158: 1774-1782. CrossRef PubMed
9. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry. 2001; 58: 1161-1167. CrossRef PubMed
10. Hennessy S, Bilker WB, Knauss JS, Margolis DJ, Kimmel SE, Reynolds RF, Glasser DB, Morrison MF, Strom BL. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ. 2002; 325: 1070. CrossRef PubMed
11. Straus SM, Bleumink GS, Dieleman JP, van der Lei J, 't Jong GW, Kingma JH, Sturkenboom MC, Stricker BH. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med. 2004; 164: 1293-1297. CrossRef PubMed
12. Ozeki Y, Fujii K, Kurimoto N, Yamada N, Okawa M, Aoki T, Takahashi J, Ishida N, Horie M, Kunugi H. QTc prolongation and antipsychotic medications in a sample of 1017 patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010; 34: 401-405. CrossRef PubMed
13. Westfall PH, Young SS. Resampling-based multiple testing: examples and methods for p-value adjustment. New York: Wiley; 1993.
14. Bloomfield DM, Kost JT, Ghosh K, Hreniuk D, Hickey LA, Guitierrez MJ, Gottesdiener K, Wagner JA. The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharmacol Ther. 2008; 84: 475-480. CrossRef PubMed
15. Garnett CE, Beasley N, Bhattaram VA, Jadhav PR, Madabushi R, Stockbridge N, Tornøe CW, Wang Y, Zhu H, Gobburu JV. Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review. J Clin Pharmacol. 2008; 48: 13-18. CrossRef PubMed
16. Malik M, Hnatkova K, Schmidt A, Smetana P. Electrocardiographic QTc changes due to moxifloxacin infusion. J Clin Pharmacol. 2009; 49: 674-683. CrossRef PubMed
17. Taubel J, Ferber G, Lorch U, Batchvarov V, Savelieva I, Camm AJ. Thorough QT study of the effect of oral moxifloxacin on QTc interval in the fed and fasted state in healthy Japanese and Caucasian subjects. Br J Clin Pharmacol. 2014; 77: 170-179. CrossRef PubMed
18. Florian JA, Tornøe CW, Brundage R, Parekh A, Garnett CE. Population pharmacokinetic and concentration - QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies. J Clin Pharmacol. 2011; 51: 1152-1162. CrossRef PubMed
19. Sager PT, Nebout T, Darpo B. ICH E14: A new regulatory guidance on the clinical evaluation of QT/QTC internal prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Drug Inf J. 2005; 39: 387-394.
20. Cutler NR. Pharmacokinetic studies of antipsychotics in healthy volunteers versus patients. J Clin Psychiatry. 2001; 62 (Suppl 5): 10-13., discussion 23-24. PubMed
21. Miceli JJ, Tensfeldt TG, Shiovitz T, Anziano R, O'Gorman C, Harrigan RH. Effects of oral ziprasidone and oral haloperidol on QTc interval in patients with schizophrenia or schizoaffective disorder. Pharmacotherapy. 2010; 30: 127-135. CrossRef PubMed
22. Potkin SG, Preskorn S, Hochfeld M, Meng X. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone. J Clin Psychopharmacol. 2013; 33: 3-10. CrossRef PubMed